{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:47:18Z","timestamp":1792172838453,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116182","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:58:47Z","timestamp":1765526327000},"page":"116182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cardiotoxic effects of BRAF\/MEK inhibition: An observational study"],"prefix":"10.1016","volume":"233","author":[{"given":"Jannek","family":"Brauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Scheidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Romann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Zehender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz H.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1-2","key":"10.1016\/j.ejca.2025.116182_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.seminoncol.2023.03.003","article-title":"Improved outcomes in women with BRAF-mutant melanoma treated with BRAF\/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis","volume":"50","author":"Pala","year":"2023","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.116182_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.116182_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2025.116182_bib4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ejca.2025.116182_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ejca.2025.116182_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/0284186X.2021.1992010","article-title":"Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting","volume":"61","author":"Pedersen","year":"2022","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116182_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010141","article-title":"BRAF and MEK inhibitors and their toxicities: a meta-analysis","volume":"15","author":"Garutti","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ejca.2025.116182_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ejca.2025.116182_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejca.2025.116182_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2340\/1651-226X.2025.42567","article-title":"Cardiotoxicity in patients with metastatic melanoma treated with BRAF\/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility","volume":"64","author":"Oddershede","year":"2025","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116182_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaccao.2023.04.004","article-title":"Cardiotoxicity of BRAF\/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores","volume":"5","author":"Glen","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.116182_bib12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaccao.2023.09.006","article-title":"Cardiotoxicity of BRAF\/MEK inhibitors according to HFA\/ICOS cardiotoxicity risk category","volume":"5","author":"Courand","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.116182_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00392-021-01894-z","article-title":"The Heidelberg cardio-oncology unit (COUNT)-a possible blueprint for improved care of cardio-oncological patients","volume":"111","author":"Lehmann","year":"2022","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"10.1016\/j.ejca.2025.116182_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1373\/clinchem.2009.132654","article-title":"Analytical validation of a high-sensitivity cardiac troponin T assay","volume":"56","author":"Giannitsis","year":"2010","journal-title":"Clin Chem"},{"issue":"9-10","key":"10.1016\/j.ejca.2025.116182_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cca.2010.12.034","article-title":"Multicenter analytical evaluation of a high-sensitivity troponin T assay","volume":"412","author":"Saenger","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"41","key":"10.1016\/j.ejca.2025.116182_bib16","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejca.2025.116182_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030986","article-title":"Global longitudinal strain in cardio-oncology: a review","volume":"15","author":"Slawinski","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ejca.2025.116182_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.ejca.2025.116182_bib19","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.116182_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","article-title":"Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale","volume":"90","author":"Rose","year":"2010","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.ejca.2025.116182_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc Toxicol"},{"issue":"6","key":"10.1016\/j.ejca.2025.116182_bib22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","article-title":"Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload","volume":"110","author":"Harris","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejca.2025.116182_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cvr\/cvu024","article-title":"B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophy","volume":"102","author":"Kramann","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"16","key":"10.1016\/j.ejca.2025.116182_bib24","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/01.CIR.0000127126.73759.23","article-title":"MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo","volume":"109","author":"Lips","year":"2004","journal-title":"Circulation"},{"issue":"100","key":"10.1016\/j.ejca.2025.116182_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yjmcc.2014.03.002","article-title":"Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction","volume":"72","author":"Ulm","year":"2014","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"10.1016\/j.ejca.2025.116182_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ejca.2025.116182_bib27","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1002\/cam4.3938","article-title":"Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries","volume":"10","author":"Guha","year":"2021","journal-title":"Cancer Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T17:01:39Z","timestamp":1767718899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"alternative-id":["S0959804925010688"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116182","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiotoxic effects of BRAF\/MEK inhibition: An observational study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116182"}}